FDA takes actions to ensure the safety, effectiveness of LDTs
- Earlier this week, on April 29, 2024, the United States FDA issued a press release announcing its actions toward ensuring the safety and effectiveness of laboratory developed tests (LDTs). According to the administration, LDTs are considered in vitro diagnostic products (IVDs) for clinical use. These tests are designed, manufactured, and used...
More Articles
National Cancer Institute Launches Precision Medicine Initiative
On June 1, 2023, the National Cancer Institute (NCI), a subset of the NIH, launched ComboMATCH, a precision medicine initiative for cancer patients. ComboMATCH — short for Combination Therapy...Michigan Blue Launches Pharmacogenomics Precision Medicine Program
Blue Care Network recently announced the launch of Michigan’s first end-to-end pharmacogenomics precision medicine program, Blue Cross Personalized Medicine. This program leverages genetic...UC Berkeley Loses CRISPR Gene-Editing Patent Appeal
The US Patent and Trademark Office (PTAB) recently ruled that CRISPR gene-editing technology belongs to the Broad Institute of Harvard and MIT, according to multiple news sources. After an...Thermo Fisher Introduces Protein To Advance CRISPR Gene Editing
Thermo Fisher Scientific recently introduced its new protein, Invitrogen TrueCut HiFi Cas9 Protein, to complement its growing CRISPR gene editing solutions portfolio. CRISPR technology has become...Pfizer, AbbVie, Biogen Launch Resource for Genetic Variants
Pfizer, AbbVie, and Biogen recently launched the world’s largest browsable resource linking rare protein-coding genetic variants to human health and disease. The genetic exome sequence...Sponsored by Pure Storage
